Research & Development: Page 59
-
PharmaVoice Team/PharmaVoice
The New Frontier: Therapeutic Vaccines
By Denise Myshko Researchers continue to evaluate the sustainability of powering the immune system to treat cancers and other serious diseases. For years researchers have been trying to find a way to trigger the body’s immune system to recognize cancers and other diseases. Early attempts to use c...
By Denise Myshko • Aug. 29, 2011 -
PharmaVoice Team/PharmaVoice
Public Service: Improving Adherence
By Robin Robinson For the next three years, the National Consumer League and its 100 partners will focus on improving adherence for chronic diseases. With almost 75% of patients in the United States not taking medicine as prescribed by their doctors, the public awareness campaign, Script Your Fut...
By Robin Robinson • Aug. 29, 2011 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, marketing, And R&D Trends affecting the healthcare industry By Carolyn Gretton U.S. Prescription Drug Spending Posts Modest Increase for 2010 Trend: Fewer physician office visits and new therapy starts indicate that U.S. patients are scaling back their use of prescription medicines ami...
By Carolyn Gretton • Aug. 29, 2011 -
PharmaVoice Team/PharmaVoice
UpFront
UpFront Awards… » CSL Behring Receives NORD Award CSL Behring has received the National Organization for Rare Disorders (NORD) 2011 Corporate Award for new treatments brought to market for patients with rare diseases. CSL Behring’s new treatment, Factor XIII concentrate (human), is approved fo...
By PharmaVoice Team • Aug. 29, 2011 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
The New Market Frontier New segmentation techniques might just be the way to uncover the next growth opportunity for brands. Audience segmentation has been around forever and is used by most companies to identify those consumers who are the right fit for their brands — and companies are spending ...
By Taren Grom • Aug. 29, 2011 -
PharmaVoice Team/PharmaVoice
2011 PharmaVOICE 100 - Who's on the List by Section
The Commanders & Chiefs Frank Baldino Jr., Ph.D. Cephalon Inc. Donna Beardsworth. Beardsworth Group Calep A. (Joe) Boyd III MCS Healthcare Public Relations Randall Carpenter, M.D. Seaside Therapeutics N. Anthony Coles, M.D. Onyx Pharmaceuticals B. Reid Connolly evoke interaction Donna Cryer C...
By PharmaVoice Team • July 26, 2011 -
PharmaVoice Team/PharmaVoice
Talent Pool
Executive appointments and promotions in the healthcare industry By Carolyn Gretton Pharmaceutical POOL Damian BRAGA Sanofi Pasteur Consolidates Commercial Operations Leadership Sanofi Pasteur, the vaccines division of global healthcare company Sanofi, has tapped U.S. President Damian Braga as s...
By Carolyn Gretton • July 26, 2011 -
PharmaVoice Team/PharmaVoice
2011 PharmaVOICE 100 - Who's on the List by Company
Acorda Therapeutics Andrew Blight, Ph.D. ACT Biotech Inc. Ali Fattaey, Ph.D. Acucela Inc. Ryo Kubota, M.D., Ph.D. Alliance Healthcare Information LLC Mary Anne Greenberg Almac Group Sir Allen McClay The Avoca Group Inc. Patricia Leuchten AXON US Mario Nacinovich Beardsworth Group Donna Beardswort...
By PharmaVoice Team • July 26, 2011 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Taking Inspiration to the Next Level This is our favorite issue of the year, and we hope it’s yours too. It has been a joy and a privilege to have had a chance to get to know this year’s PharmaVOICE 100. They certainly illustrate what it means to think bigger, do more, and lead with passion and i...
By Taren Grom • July 26, 2011 -
PharmaVoice Team/PharmaVoice
Managing Outsourced Development: Designing a Performing Process
Ronald S. Waife, MPH, President With the rise of mega-CROs, and the widespread willingness of large pharma to outsource clinical development to them, is there anything left for a sponsor’s clinical development group to do? Indeed yes. More than ever, there are hyper-critical functions that sponso...
By Ronald S. Waife • May 25, 2011 -
PharmaVoice Team/PharmaVoice
Industry Experts Challenge the Status Quo on Content Management
For more than two decades, life sciences organizations have purchased, customized, configured, deployed, and maintained a series of ever-expanding and complex content management tools to help them efficiently manage content. The creation of industry-specific applications added to these technologi...
By Ian Talmage • May 25, 2011 -
PharmaVoice Team/PharmaVoice
Clinical Data Gap Analysis Uncovering Hidden Opportunities
David Fishman, MBA President Snowfish LLC The practice of medicine relies on clinical evidence. From a product’s conception through approval, launch, and post-launch activities, clinical evidence is the rationale for a product’s overall existence. Clinical data is critical for differentiation and...
By David Fishman • May 25, 2011 -
PharmaVoice Team/PharmaVoice
Metrics for Faster Clinical Trials
Almost half of clinical trials run late, year after year. Why does this happen? The biggest delaying factor is finding enough patients, and the delay starts with the clinical trial protocol. The protocol includes the inclusion and exclusion criteria that define the patients who are eligible for t...
By Bill Gwinn • May 25, 2011 -
PharmaVoice Team/PharmaVoice
Bringing Process Efficiency to Clinical Trial Randomization
Modern business has fully embraced the benefits of process efficiency. From the widespread adoption of process improvement as driven by Michael Hammer, author of “Reengineering the Corporation," its evolution to the Six Sigma movement, to the more recent “lean sigma" approach, process efficiency ...
By PharmaVoice Team • May 25, 2011 -
PharmaVoice Team/PharmaVoice
Partnering with CROs: Achieving Operational Excellence
Our industry is facing a challenge. In 2010, the FDA approved only 21 new drugs, down from 26 in 2009 and 24 in 2008. To counteract this decrease, biopharmaceutical companies are increasingly anxious to launch their products as quickly as possible to benefit from related revenue sooner. One way t...
By PharmaVoice Team • May 25, 2011 -
PharmaVoice Team/PharmaVoice
Effective Use of Health Technology Assessment to Maximize Market Access: Start Early and Update Often
We all know that the face of drug discovery and the market for new pharmaceutical products (and medical devices/diagnostic technologies) is changing. The era of the blockbuster appears to be over, the cost of bringing a new product to market has skyrocketed and when a new product is eventually li...
By Andrew Briggs • May 25, 2011 -
PharmaVoice Team/PharmaVoice
Understanding the Finer Points of the Electronic Source Documentation Draft Guidance
For those involved with collecting data generated by clinical trials, the recent draft guidance on electronic source documentation released by the FDA deserves your scrutiny. The impact of this guidance for sites is significant and the implications for CRAs, data managers, and technology vendors ...
By Jonathan Andrus VP • May 25, 2011 -
PharmaVoice Team/PharmaVoice
Merhaba, Turkey: Opportunity Knocks
As the largest pharmaceutical market in the Middle East and the fastest growing in the Mediterranean region, Turkey presents some exciting opportunities for the pharmaceutical market. Consumption of pharmaceuticals in Turkey totals around $8 billion, with 50% of these drugs being manufactured dom...
By Kim Ribbink • May 24, 2011 -
PharmaVoice Team/PharmaVoice
Changing Oncology Regulations
Developing oncology therapies can be complex. These products often have a tough time making it to the market. In fact, a study released in February by the Biotechnology Industry Organization and BioMedTracker shows that oncology products had the lowest Phase III success rate among seven therapeut...
By Denise Myshko • May 24, 2011 -
PharmaVoice Team/PharmaVoice
Educating the Scientists of the Future
High-quality science education is critical for the success of pharmaceutical and biotechnology companies, not only to meet the need for scientists in the future but also to foster scientific literacy. Education reform is a hot-button issue for the nation in general and the pharmaceutical industr...
By Denise Myshko • May 24, 2011 -
PharmaVoice Team/PharmaVoice
DIA Preview
New Tools, Services, and Products Designed to Improve Drug Development This special Drug Information Association section highlights the new and innovative products being offered by companies exhibiting at the upcoming 2011 DIA — 47th Annual Meeting in Chicago. (Note: briefs are listed alphabetic...
By PharmaVoice Team • May 24, 2011 -
PharmaVoice Team/PharmaVoice
R&D's Technology Evolution
Technology tools are the cornerstones for achieving a drug development process that is faster, cheaper, and easier. Over the last 10 years, there has been increasing use of EDC, ePRO, CTMS, dashboards, and other tools to streamline the drug development process. Now a changing R&D paradigm is ...
By Denise Myshko • May 24, 2011 -
PharmaVoice Team/PharmaVoice
Pharma 3.0: A Call for Collaboration and Experimentation
Success or failure in Pharma 3.0 — an ecosystem comprised of established industry members, nontraditional companies, and an increasingly informed data-empowered consumer — will be based on life-sciences companies’ ability to develop innovative, outcomes-focused offerings through structured, syste...
By Robin Robinson • May 24, 2011 -
PharmaVoice Team/PharmaVoice
Last Word
Combating Drug Resistance Roger Pomerantz, M.D., Senior VP and Head of Infectious Disease Research at Merck, talks about why antimicrobial resistance is a major global concern. PV: How big of a problem is antimicrobial resistance? Pomerantz: For the first time since the antibiotic era started in...
By PharmaVoice Team • May 24, 2011 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Dr. Janet HAMMOND Roche Strengthens Translational Medicine Leadership Roche has appointed Janet Hammond, M.D., Ph.D., VP, translational medicine – virology in pharmaceutical research and early development (pRED). Dr. Hammond joins Roche from Valeant Pharmaceuticals Internation...
By PharmaVoice Team • May 24, 2011
Previous
